TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

Conditions:   Breast Adenocarcinoma;   Stage II Breast Cancer AJCC v6 and v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7 ;   Stage IIIC Breast Cancer AJCC v7 Interventions:   Biological: Pertuzumab;   Other: Placebo Administration;   Biological: Sargramostim;   Biological: Trastuzumab;   Biological: Trastuzumab Emtansine;   Biological: Vaccine Therapy Sponsors:   Mayo Clinic;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials